financetom
Business
financetom
/
Business
/
Artisan Partners opposes Japan retailer Seven & i's CEO choice
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Artisan Partners opposes Japan retailer Seven & i's CEO choice
Mar 9, 2025 11:49 AM

(Reuters) - Artisan Partners, a U.S.-based investor in Seven & i Holdings ( SVNDF ), on Sunday opposed the Japanese retailer's CEO succession plan and urged the company to reconsider a takeover offer, according to a letter to the board.

Last week, the 7-Eleven convenience store operator named Stephen Dacus as CEO to lead its recovery and respond to a $47 billion takeover offer from Canada's Alimentation Couche-Tard ( ANCTF ).

In the letter, Artisan Partners opposed Dacus's selection and urged Seven & i ( SVNDF ) to engage with Couche-Tard about its buyout proposal to maximize shareholder value.

Couche-Tard did not immediately respond to a Reuters request for comment, while Seven & i ( SVNDF ) wasn't immediately available for comment outside business hours.

The special committee and Dacus rejected Couche-Tard's offer of $18.19 per share, which at the time was a premium of almost one-third from the current share price. However, the company's shares closed at $14.18 on Friday in Tokyo, about 22% below Couche-Tard's latest offer.

The activist investor said it will vote against Dacus at the company's upcoming annual general meeting, as well as against other members of the nomination committee.

Artisan Partners said it would also vote against Seven & I ( SVNDF ) Vice President Junro Ito at the annual general meeting, citing his inability to secure financing for a $58 billion management buyout last month.

The Ito family began talks to take the convenience store owner private in what would have been the largest management buyout in history if successful after Seven & i ( SVNDF ) received the Couche-Tard bid last year.

Artisan is among Seven & i's ( SVNDF ) foreign investors that have urged the company to focus on its core convenience store business.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
China has shown 'utmost sincerity' over China-EU EV tariff talks, ministry says
China has shown 'utmost sincerity' over China-EU EV tariff talks, ministry says
Jul 8, 2024
BEIJING (Reuters) - China has shown the utmost sincerity over consultations relating to a European Union investigation into electric vehicle subsidies, and a comment attributed to an EU official is grossly inconsistent with the facts, the commerce ministry said on Monday. Jorge Toledo, the EU's ambassador to China, was quoted by media as saying Beijing had only recently responded to...
Boeing in talks with US defense department on impact of guilty plea - source
Boeing in talks with US defense department on impact of guilty plea - source
Jul 8, 2024
WASHINGTON (Reuters) - Boeing is in talks with the U.S. Defense Department over how the planemaker's planned guilty plea could affect its extensive government contracts, a person briefed on the matter said. Late on Sunday, the Justice Department said in a court filing that Boeing had agreed to plead guilty to a criminal fraud conspiracy charge to resolve an investigation...
Jaguar Health Unit Secures New European, Australian Patents; Shares Rise
Jaguar Health Unit Secures New European, Australian Patents; Shares Rise
Jul 8, 2024
11:21 AM EDT, 07/08/2024 (MT Newswires) -- Jaguar Health ( JAGX ) unit Napo Pharmaceuticals said Monday it secured new patents from the European and Australian patent offices for its plant-based prescription drug crofelemer. The European patent covers methods for treating short bowel syndrome, bile acid diarrhea, and diarrhea related to small intestine resection or gallbladder removal with an inhibitor...
Mirum Pharmaceuticals Gets Marketing Approval for Livmarli in Europe
Mirum Pharmaceuticals Gets Marketing Approval for Livmarli in Europe
Jul 8, 2024
11:20 AM EDT, 07/08/2024 (MT Newswires) -- Mirum Pharmaceuticals ( MIRM ) said Monday that the European Commission has approved the marketing of its oral treatment Livmarli for progressive familial intrahepatic cholestasis, or PFIC, in patients aged 3 months or more. PFIC is a disorder that causes progressive liver disease. The approval is based on a phase 3 study, which...
Copyright 2023-2026 - www.financetom.com All Rights Reserved